Optimizing Combination Therapies with Existing and Future CML Drugs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Sep 3

PMID 20808800

Citations 13

Authors

Allen A Katouli

Natalia L Komarova

Affiliations

Soon will be listed here.

Abstract

Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new inhibitors. Many new compounds active against T315I mutants are now at different stages of development. In this paper we develop an algorithm which can weigh different combination treatment protocols according to their cross-resistance properties, and find the protocols with the highest probability of treatment success. This algorithm also takes into account drug toxicity by minimizing the number of drugs used, and their concentration. Although our methodology is based on a stochastic model of CML microevolution, the algorithm itself does not require measurements of any parameters (such as mutation rates, or division/death rates of cells), and can be used by medical professionals without a mathematical background. For illustration, we apply this algorithm to the mutation data obtained in [1], [2].

Citing Articles

Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone.

Malik V, Radhakrishnan N, Kaul S, Wadhwa R, Sundar D Biomolecules. 2022; 12(2).

PMID: 35204712 PMC: 8961606. DOI: 10.3390/biom12020212.

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.

Lindstrom H, Friedman R BMC Cancer. 2020; 20(1):397.

PMID: 32380976 PMC: 7204252. DOI: 10.1186/s12885-020-06782-9.

Towards natural mimetics of metformin and rapamycin.

Aliper A, Jellen L, Cortese F, Artemov A, Karpinsky-Semper D, Moskalev A Aging (Albany NY). 2017; 9(11):2245-2268.

PMID: 29165314 PMC: 5723685. DOI: 10.18632/aging.101319.

Bioactivity in : A Systemic Analysis of Antimicrobial and Cytotoxic Activities and Their Phylogenetic and Phytochemical Origins.

Grimbs A, Shrestha A, Rezk A, Grimbs S, Said I, Schepker H Front Plant Sci. 2017; 8:551.

PMID: 28450876 PMC: 5390042. DOI: 10.3389/fpls.2017.00551.

Optimized Treatment Schedules for Chronic Myeloid Leukemia.

He Q, Zhu J, Dingli D, Foo J, Leder K PLoS Comput Biol. 2016; 12(10):e1005129.

PMID: 27764087 PMC: 5072565. DOI: 10.1371/journal.pcbi.1005129.

References

Noronha G, Cao J, Chow C, Dneprovskaia E, Fine R, Hood J . Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008; 8(10):905-21. DOI: 10.2174/156802608784911635. View

Komarova N . Stochastic modeling of drug resistance in cancer. J Theor Biol. 2005; 239(3):351-66. DOI: 10.1016/j.jtbi.2005.08.003. View

Rix U, Hantschel O, Durnberger G, Remsing Rix L, Planyavsky M, Fernbach N . Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12):4055-63. DOI: 10.1182/blood-2007-07-102061. View

de Pillis L, Gu W, Fister K, Head T, Maples K, Murugan A . Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math Biosci. 2007; 209(1):292-315. DOI: 10.1016/j.mbs.2006.05.003. View

Gaffney E . The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J Math Biol. 2004; 48(4):375-422. DOI: 10.1007/s00285-003-0246-2. View

COJOCARU L, Agur Z . A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math Biosci. 1992; 109(1):85-97. DOI: 10.1016/0025-5564(92)90053-y. View

Vajpai N, Strauss A, Fendrich G, Cowan-Jacob S, Manley P, Grzesiek S . Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem. 2008; 283(26):18292-302. DOI: 10.1074/jbc.M801337200. View

Druker B . Imatinib as a paradigm of targeted therapies. Adv Cancer Res. 2004; 91:1-30. DOI: 10.1016/S0065-230X(04)91001-9. View

Giles F, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman S . MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2006; 109(2):500-2. DOI: 10.1182/blood-2006-05-025049. View

10.

Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004; 45(11):2197-203. DOI: 10.1080/10428190410001723278. View

11.

Zhang J, Adrian F, Jahnke W, Cowan-Jacob S, Li A, Iacob R . Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010; 463(7280):501-6. PMC: 2901986. DOI: 10.1038/nature08675. View

12.

Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y . Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res. 2008; 32(6):980-3. DOI: 10.1016/j.leukres.2007.11.008. View

13.

Daub H, Specht K, Ullrich A . Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004; 3(12):1001-10. DOI: 10.1038/nrd1579. View

14.

Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R . Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 2007; 67(17):7987-90. DOI: 10.1158/0008-5472.CAN-07-1825. View

15.

Apperley J . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11):1018-29. DOI: 10.1016/S1470-2045(07)70342-X. View

16.

Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S . Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des. 2007; 70(3):171-81. DOI: 10.1111/j.1747-0285.2007.00556.x. View

17.

Kendal W, Frost P . Genomic instability, tumor heterogeneity and progression. Adv Exp Med Biol. 1988; 233:1-4. DOI: 10.1007/978-1-4899-5037-6_1. View

18.

Nardi V, Azam M, Daley G . Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2003; 11(1):35-43. DOI: 10.1097/00062752-200401000-00006. View

19.

Gontarewicz A, Brummendorf T . Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res. 2010; 184:199-214. DOI: 10.1007/978-3-642-01222-8_14. View

20.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M . Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2008; 27(3):469-71. DOI: 10.1200/JCO.2008.19.8853. View